作用于过氧化物酶体增殖物激活受体药物的研究进展

被引：2

作者：

项芬芬 ^{[1
]}

张学梅 ^{[1
]}

马艳 ^{[1
]}

段薇 ^{[2
]}

机构：

[1] 大连大学医学院

[2] 大连大学附属中山医院内分泌科

来源：

生命科学研究 | 2015年 / 19卷 / 04期

关键词：

过氧化物酶体增殖物激活受体(PPARs); 激动剂; 炎症; 肿瘤; 代谢性疾病;

D O I：

10.16605/j.cnki.1007-7847.2015.04.017

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是被脂肪酸等内源性配体、外源性过氧化物酶体增殖剂(peroxisome proliferators,PP)激活,进而调控参与脂类代谢某些酶基因表达的转录调节因子。PPARs与糖脂代谢性疾病、炎症及某些肿瘤的发生发展密切相关。PPARs激动剂和其部分激动剂主要用于治疗糖尿病,另外其拮抗剂同其一样也用于炎症和肿瘤的治疗。现就作用于PPARs药物的研究进展进行了综述。

引用

页码：372 / 376

页数：5

共 15 条

[1] PPAR-γ在肝门部胆管癌中的表达及其配体激活后对胆管癌细胞的作用 [J].

程文 ;

程南生 ;

熊先泽 ;

夏庆杰 ;

陈清英 ;

闫乃红 ;

敬静 .

四川大学学报(医学版), 2006, (05) :745-749

[2] The Dipeptide H-Trp-Arg-OH (WR) Is a PPARα Agonist and Reduces Hepatic Lipid Accumulation in Lipid-Loaded H4IIE Cells [J].

Jia, Yaoyao ;

Kim, Jong-Ho ;

Nam, Bora ;

Kim, Jiyoung ;

Lee, Ji Hae ;

Kim, Kyung Ok ;

Hwang, Kwang Yeon ;

Lee, Sung-Joon .

APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2015, 175 (02) :1211-1220

[3] Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats [J].

Shim, Chi Young ;

Song, Byeong-Wook ;

Cha, Min-Ji ;

Hwang, Ki-Chul ;

Park, Sungha ;

Hong, Geu-Ru ;

Kang, Seok-Min ;

Lee, Jong Eun ;

Ha, Jong-Won ;

Chung, Namsik .

JOURNAL OF DIABETES INVESTIGATION, 2014, 5 (04) :362-371

[4] The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer [J].

Forootan, Farzad S. ;

Forootan, Shiva S. ;

Malki, Mohammed I. ;

Chen, Danqing ;

Li, Gandi ;

Lin, Ke ;

Rudland, Philip S. ;

Foster, Christopher S. ;

Ke, Youqiang .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (01) :265-275

[5]

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects[J] . Bertrand Cariou,Rémy Hanf,Stéphanie Lambert-Porcheron,Yassine Za?r,Valérie Sauvinet,Benoit No?l,Laurent Flet,Hubert Vidal,Bart Staels,Martine Laville.Diabetes Care . 2013 (10)

[6]

Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor α–Dependent and Independent Mechanisms in Human Endothelial Cells[J] . Corine Glineur,Barbara Gross,Bernadette Neve,Corinne Rommens,Gerard T. Chew,Fran?oise Martin-Nizard,Fernando Rodríguez-Pascual,Santiago Lamas,Gerald F. Watts,Bart Staels.Arteriosclerosis, Thrombosis, and Vascular Biology . 2013 (3)

[7]

Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk[J] . Giuseppe Derosa,Pamela Maffioli.Current Molecular Pharmacology . 2012 (2)

[8]

Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors[J] . MichelDietz,PeterMohr,BerndKuhn,Hans PeterMaerki,PeterHartman,ArminRuf,J?rgBenz,UweGrether,Matthew B.Wright.ChemMedChem . 2012 (6)

[9] Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes [J].

Dunn, Fredrick L. ;

Higgins, Linda S. ;

Fredrickson, Jill ;

DePaoli, Alex M. .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2011, 25 (03) :151-158

[10]

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis[J] . Meng Lee,Jeffrey L. Saver,Amytis Towfighi,Jessica Chow,Bruce Ovbiagele.Atherosclerosis . 2011 (2)

← 1 2 →